Product Details
| Product Name:
KDU691 |
CAS No.:
1513879-19-0 |
| Purity:
98.68% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | KDU691 |
| Description | KDU691 is a PI4K inhibitor. |
| Animal Research | Sporozoites were harvested from P. cynomolgi-infected mosquitoes, washed with phosphate-buffered saline (PBS), and diluted to 100,000 sporozoites (spz)/ml in PBS. One-milliliter aliquots of sporozoites were prepared and injected into monkeys via intravenous injection. During treatment, monkeys were weighed daily and received the compound via gavage, followed by gastric feeding. Monkeys in the prophylaxis groups were treated 20 min after the i.v. sporozoite injection. The other monkeys were treated when all the monkeys in the experiment (except those in the prophylaxis group) were blood-stage patent (at day 11 p.i.). To kill the blood-stage parasites, all monkeys received a 5-day treatment of 7.5 mg/kg of body weight of chloroquine (CQ), during compound dosing. KDU691 was formulated in 0.5% methylcellulose and 0.5% Tween 80 in water. LMV599 was formulated as a solid dispersion in a solution containing 5.6% (wt/wt) Tween 80 44.4% hydroxypropyl methylcellulose (HPMC) E3 38.9% Soluplus 11.1% vitamin E d-alphatocopheryl polyethylene glycol 1000 succinate. |
| In vivo | KDU691 was evaluated for in vivo activity in rhesus macaques infected with P. cynomolgi sporozoites.?The prophylactically treated monkeys failed to become blood smear positive, while untreated control animals showed normal parasitemia development (primary parasitemia at day 8.9 p.i., with the first relapse within a month).?Thus, 5-day oral treatment with 20 mg/kg of KDU691 shortly after infection eradicated all liver-stage parasites, including hypnozoites. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 150 mg/mL (357.26 mM)
|
| Keywords | PI4 kinases | blood | Inhibitor | liver | Phosphatidylinositol 4 kinases | ring-stage | falciparum | Parasite | plasmodium | schizonts | KDU691 | gametocytes | PI4K | inhibit | KDU 691 | KDU-691 | stage |
| Inhibitors Related | Picaridin | PHYTOL | Kaempferol | Hydroxychloroquine | Metronidazole | Nitazoxanide | Doxycycline | Chloroquine phosphate | Diethyltoluamide | Artemisinin | Benzyl benzoate | DL-Methionine |
| Related Compound Libraries | Reprogramming Compound Library | Glycolysis Compound Library | Anti-Parasitic Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1415407-60-1
$30.00 / 1mg
-
CAS:1675201-90-7
$33.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States